Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High – Here’s Why

Definium Therapeutics, Inc. (NASDAQ:DFTX) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $20.41 and last traded at $20.40, with a volume of 570077 shares trading hands. The stock had previously closed at $18.90.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Wolfe Research initiated coverage on shares of Definium Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $25.00 price target on the stock. Royal Bank Of Canada upped their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Needham & Company LLC reissued a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Definium Therapeutics in a report on Monday, February 2nd. Finally, JonesTrading started coverage on Definium Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Definium Therapeutics presently has a consensus rating of “Buy” and an average target price of $35.70.

Definium Therapeutics Stock Performance

The company has a market cap of $2.02 billion, a price-to-earnings ratio of -9.53 and a beta of 2.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. The firm has a fifty day simple moving average of $17.49 and a 200 day simple moving average of $14.18.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DFTX. Royal Bank of Canada raised its holdings in Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after acquiring an additional 6,148 shares during the period. Geode Capital Management LLC boosted its holdings in Definium Therapeutics by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock valued at $11,252,000 after acquiring an additional 66,663 shares during the period. Creative Planning grew its position in shares of Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. Swiss National Bank grew its position in shares of Definium Therapeutics by 8.0% in the second quarter. Swiss National Bank now owns 115,100 shares of the company’s stock valued at $747,000 after purchasing an additional 8,500 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Definium Therapeutics by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after purchasing an additional 2,342 shares during the period. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.